Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + lenvatinib + pembrolizumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), lenvatinib (a kinase inhibitor), pembrolizumab (an immune checkpoint inhibitor), and pemetrexed (a folate analog metabolic inhibitor). While individual components and some combinations of these drugs are used in cancer treatment, this specific four-drug combination is not clearly documented in the provided search results.
02
Targets
GART (GAR transformylase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)DHFR (Dihydrofolate reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on carboplatin + lenvatinib + pembrolizumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + lenvatinib + pembrolizumab + pemetrexed.